Target intelligence / Profile preview

Tight junction protein 1 (TJP1)

Target
TJP1
Molecular classification
Scaffolding protein, Membrane-associated guanylate kinase (MAGUK), PDZ domain-containing protein
01

Overview

Tight junction protein 1 (TJP1), also known as Zonula occludens-1 (ZO-1), is a high-molecular-weight scaffolding protein that is a primary component of the tight junction complex in epithelial and endothelial cells [1]. It contains three PDZ domains, an SH3 domain, and a GUK domain, which allow it to cross-link transmembrane proteins such as claudins, occludins, and junctional adhesion molecules (JAMs) to the actin cytoskeleton [2]. This structural role is vital for maintaining the gate and fence functions of tight junctions, regulating the paracellular movement of ions and solutes while maintaining cell polarity [3]. In diseases like celiac disease and inflammatory bowel disease, TJP1 is often downregulated or redistributed, leading to leaky barriers [4]. Conversely, in oncology, TJP1 expression is frequently altered during epithelial-mesenchymal transition (EMT), contributing to tumor progression and metastasis [5]. Pharmacological modulation of TJP1, particularly through its PDZ domains, is a strategy used to either stabilize the barrier (e.g., Larazotide in celiac disease) or transiently increase permeability for enhanced drug delivery across the blood-brain barrier [6]. Sources: [1] UniProt Consortium. Tight junction protein ZO-1. UniProtKB - Q07157. [2] Fanning, A. S., & Anderson, J. M. (2009). Zonula occludens-1 and -2 are cytosolic scaffolds that regulate the assembly of tight junctions. Annals of the New York Academy of Sciences. [3] Van Itallie, C. M., & Anderson, J. M. (2014). Architecture of tight junctions and principles of molecular composition. Seminars in Cell & Developmental Biology. [4] Fasano, A. (2011). Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiological Reviews. [5] Polette, M., et al. (2007). Zonula occludens-1 expression and distribution in human neoplasia. Advanced Drug Delivery Reviews. [6] Roudnicky, F., et al. (2020). Targeting the PDZ domains of TJP1 for barrier modulation. Journal of Controlled Release.

Other names
Zonula occludens-1ZO-1Tight junction protein ZO-1Zonula occludens protein 1
02

Mechanism of action

Regulation of tight junction assembly and paracellular permeability through competitive binding or stabilization of PDZ-mediated protein-protein interactions.

03

Biological functions

Tight junction assemblyParacellular permeability regulationCell polarity maintenanceCytoskeletal organizationSignal transduction
04

Disease associations

Celiac diseaseInflammatory bowel diseaseCancer metastasisDiabetic retinopathyBlood-brain barrier disruptionViral infection
05

Safety considerations

Risk of systemic infection due to barrier breachTissue edemaLoss of cell polarityPotential for promoting metastasis if chronically inhibited
06

Interacting drugs

Larazotide

2 more in the full profile.

07

Biomarkers

ZO-1 expression (IHC)ZO-1 localization at cell-cell contactsSerum zonulin levelsParacellular permeability (lactulose/mannitol ratio)

Beyond the preview

Go deeper on Tight junction protein 1 (TJP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tight junction protein 1 (TJP1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call